Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands.

2.50
Hdl Handle:
http://hdl.handle.net/10029/621800
Title:
Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands.
Authors:
Vissers, Marloes; Wijmenga-Monsuur, Alienke J; Knol, Mirjam J; Badoux, Paul; van Houten, Marlies A; van der Ende, Arie; Sanders, Elisabeth A M; Rots, Nynke Y
Abstract:
The 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in The Netherlands in 2006 and was replaced by PHiD-CV10 in 2011. Data on carriage prevalence of S. pneumoniae serotypes in children and invasive pneumococcal disease (IPD) in children and older adults were collected to examine the impact of PCVs on carriage and IPD in The Netherlands. Pneumococcal carriage prevalence was determined by conventional culture of nasopharyngeal swabs in 24-month-old children in 2015/2016. Data were compared to similar carriage studies in 2005 (pre-PCV7 introduction), 2009, 2010/2011 and 2012/2013. Invasive pneumococcal disease isolates from hospitalized children <5 years and adults >65 years (2004-2016) were obtained by sentinel surveillance. All isolates were serotyped by Quellung. Serotype invasive disease potential was calculated using carriage and nationwide IPD data in children. The overall pneumococcal carriage rate was 48% in 2015/2016, lower than in 2010/2011 (64%) and pre-vaccination in 2005 (66%). Carriage of the previously dominant non-vaccine serotypes 19A and 11A has declined since 2010/2011, from 14.2% to 4.6% and 4.2% to 2.7%, respectively, whereas carriage of serotypes 6C and 23B has increased (4.2% to 6.7% and 3.9% to 7.3%), making serotypes 6C and 23B the most prevalent carriage serotypes. IPD incidence declined in children (20/100,000 cases in 2004/2006 to 6/100,000 cases in 2015/2016) as well as in older adults (63/100,000 cases to 51/100,000 cases). Serotypes 6C, 23B and 11A have high carriage prevalence in children, but show low invasive disease potential. Serotype 8 is the main causative agent for IPD in older adults (11.3%). In conclusion, 10 years after the introduction of pneumococcal vaccination in children in The Netherlands shifts in carriage and disease serotypes are still ongoing. Surveillance of both carriage and IPD is important to assess PCV impact and to predict necessary future vaccination strategies in both children and older adults.
Citation:
Increased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands. 2018, 13 (3):e0194823 PLoS ONE
Journal:
Plos One 2018; 13(3):e0194823
Issue Date:
2018
URI:
http://hdl.handle.net/10029/621800
DOI:
10.1371/journal.pone.0194823
PubMed ID:
29601605
Type:
Article
Language:
en
ISSN:
1932-6203
Appears in Collections:
Miscellaneous

Full metadata record

DC FieldValue Language
dc.contributor.authorVissers, Marloesen
dc.contributor.authorWijmenga-Monsuur, Alienke Jen
dc.contributor.authorKnol, Mirjam Jen
dc.contributor.authorBadoux, Paulen
dc.contributor.authorvan Houten, Marlies Aen
dc.contributor.authorvan der Ende, Arieen
dc.contributor.authorSanders, Elisabeth A Men
dc.contributor.authorRots, Nynke Yen
dc.date.accessioned2018-04-19T09:43:57Z-
dc.date.available2018-04-19T09:43:57Z-
dc.date.issued2018-
dc.identifier.citationIncreased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands. 2018, 13 (3):e0194823 PLoS ONEen
dc.identifier.issn1932-6203-
dc.identifier.pmid29601605-
dc.identifier.doi10.1371/journal.pone.0194823-
dc.identifier.urihttp://hdl.handle.net/10029/621800-
dc.description.abstractThe 7-valent pneumococcal conjugate vaccine (PCV7) was introduced in The Netherlands in 2006 and was replaced by PHiD-CV10 in 2011. Data on carriage prevalence of S. pneumoniae serotypes in children and invasive pneumococcal disease (IPD) in children and older adults were collected to examine the impact of PCVs on carriage and IPD in The Netherlands. Pneumococcal carriage prevalence was determined by conventional culture of nasopharyngeal swabs in 24-month-old children in 2015/2016. Data were compared to similar carriage studies in 2005 (pre-PCV7 introduction), 2009, 2010/2011 and 2012/2013. Invasive pneumococcal disease isolates from hospitalized children <5 years and adults >65 years (2004-2016) were obtained by sentinel surveillance. All isolates were serotyped by Quellung. Serotype invasive disease potential was calculated using carriage and nationwide IPD data in children. The overall pneumococcal carriage rate was 48% in 2015/2016, lower than in 2010/2011 (64%) and pre-vaccination in 2005 (66%). Carriage of the previously dominant non-vaccine serotypes 19A and 11A has declined since 2010/2011, from 14.2% to 4.6% and 4.2% to 2.7%, respectively, whereas carriage of serotypes 6C and 23B has increased (4.2% to 6.7% and 3.9% to 7.3%), making serotypes 6C and 23B the most prevalent carriage serotypes. IPD incidence declined in children (20/100,000 cases in 2004/2006 to 6/100,000 cases in 2015/2016) as well as in older adults (63/100,000 cases to 51/100,000 cases). Serotypes 6C, 23B and 11A have high carriage prevalence in children, but show low invasive disease potential. Serotype 8 is the main causative agent for IPD in older adults (11.3%). In conclusion, 10 years after the introduction of pneumococcal vaccination in children in The Netherlands shifts in carriage and disease serotypes are still ongoing. Surveillance of both carriage and IPD is important to assess PCV impact and to predict necessary future vaccination strategies in both children and older adults.en
dc.language.isoenen
dc.rightsArchived with thanks to PloS oneen
dc.titleIncreased carriage of non-vaccine serotypes with low invasive disease potential four years after switching to the 10-valent pneumococcal conjugate vaccine in The Netherlands.en
dc.typeArticleen
dc.identifier.journalPlos One 2018; 13(3):e0194823en

Related articles on PubMed

All Items in WARP are protected by copyright, with all rights reserved, unless otherwise indicated.